LIMNW

Liminatus Pharma, Inc. Warrants
LIMNW

Overview Fund Activity
1 day
5 days
1 month
3 months
6 months
Year to date
1 year
5 years
10 years
 

About: Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.

Healthcare Biotechnology
0
Funds holding %
of 7,462 funds
–
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

44.33% more ownership

Funds ownership: 0% [Q1] → 44.33% (+44.33%) [Q2]

See Fund Rankings

Financial journalist opinion

We haven’t received any recent news articles for LIMNW

See News Rankings
Charts implemented using Lightweight Charts™